Clinical Trials · NCT01890993
Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 952
- Start date
- Aug 2013
- Locations
- 4 sites, 4 countries
- Primary endpoint
- Change in HbA1c (glycosylated haemoglobin)